Fenebrutinib, a small molecule drug being investigated for multiple sclerosis, was able to reduce brain lesions in people with the disease, the developer Roche announced on 17 May. The results were obtained from a Phase 2 trial of fenebrutinib, a Bruton’s tyrosine kinase inhibitor, which is being studied in adults with relapsing forms of the disease. Data from the study showed that fenebrutinib significantly reduced the total number of new gadolinium-enhancing T1 brain lesions compared with a placebo, the primary endpoint of the trial.
